Corton Capital Inc. Vertex Pharmaceuticals Inc Transaction History

Corton Capital Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $828,436 - $1.02 Million	-2,109 Reduced 77.48%	613 $287,000
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $298,836 - $326,976	733 Added 36.85%	2,722 $1.14 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $244,559 - $292,814	713 Added 55.88%	1,989 $809,000
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $237,064 - $254,084	-701 Reduced 35.46%	1,276 $443,000
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $44,962 - $50,323	143 Added 7.8%	1,977 $695,000
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $293,992 - $335,377	1,038 Added 130.4%	1,834 $577,000
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $227,464 - $255,898	796 New	796 $229,000
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $320,485 - $399,038	-1,364 Reduced 51.22%	1,299 $366,000
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $589,641 - $694,963	2,663 New	2,663 $695,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Corton Capital Inc. with notifications on news.